Chimeric CD40 and MyD88 Adapters for Dendritic Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dendritic cell-based cancer vaccines face inefficiencies due to suboptimal activation, limited migration to lymph nodes, and short lifespan of dendritic cells, which hinder the induction of effective immune responses, and the use of prostaglandin E2 in maturation cocktails has adverse effects on immune stimulation.
Innovation Solution
A method involving the targeted temporal control of the CD40 signaling pathway using a chimeric protein with a membrane-targeting region, an FKBP ligand-binding region, and a truncated MyD88 peptide lacking the TIR domain, combined with inducible Pattern Recognition Receptor adapters, to enhance the activation and migration of dendritic cells and induce a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dendritic cells are used as antigen-presenting cells in cancer vaccines, then immune response activation is improved, but clinical efficacy is insufficient due to suboptimal activation, limited migration, and short lifespan
Solution Approach 1:
The patent combines multiple signaling pathways (CD40, TLR, and MyD88) into a unified dendritic cell activation system. By co-expressing chimeric CD40 proteins and Pattern Recognition Receptor adapters, the system merges costimulatory signaling with pathogen recognition signaling, achieving synergistic activation that overcomes the limitations of single-pathway approaches and substantially improves clinical efficacy
Solution Approach 2:
The invention uses composite molecular structures including chimeric proteins that fuse CD40 extracellular domains with MyD88 cytoplasmic domains, and composite signaling complexes formed by the interaction of multiple adapters (CD40AP, TLRAP) with their respective receptors. These composite structures enable simultaneous engagement of multiple signaling pathways, resolving the contradiction between activation quality and clinical efficacy
2Speed
If prostaglandin E2 is used in maturation cocktails to enhance dendritic cell migration, then migratory capacity is improved, but immune stimulation is suppressed
Solution Approach 1:
The patent extracts the migration-enhancing function from prostaglandin E2 by using CCR7 ligands (CCL19, CCL21) as the primary migratory stimulus. This allows selective removal of PGE2's immunosuppressive effects while preserving its beneficial migratory function through alternative pathways, thereby eliminating the harmful trade-off
Solution Approach 2:
The invention introduces CCR7-CCR7 ligand interactions as an intermediary mechanism to achieve migration without PGE2. The chemokine receptor CCR7 and its ligands serve as mediators that can drive dendritic cell migration to lymph nodes independently of prostaglandin E2, thus avoiding the immunosuppression caused by PGE2 while maintaining migratory capacity
3Reliability
If dendritic cells are fully matured with high co-stimulatory molecules, then T cell priming is maximized, but migration to lymph nodes is limited
Solution Approach 1:
The patent employs dynamic control of dendritic cell maturation states through inducible expression systems. Dendritic cells can be transitioned between immature and mature states at different time points and locations: remaining immature for optimal migration, then becoming mature upon reaching lymph nodes for T cell priming. This temporal dynamics resolves the contradiction between migration efficiency and T cell activation capability
Solution Approach 2:
The invention performs preliminary migration of dendritic cells in an immature state before they undergo maturation. By allowing dendritic cells to migrate first and then mature at the destination (lymph nodes), the system ensures optimal migratory capacity is maintained during transit, while T cell priming capability is activated only when needed at the target location
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.